{"title":"Manual Fractional Technology with CO<sub>2</sub> Laser Combined with Transdermal Drug Delivery for Hypertrophic Scar: A Retrospective Study.","authors":"Houhuang Qiu, Bingliang Wu, Fuqiang Pan, Siyuan Zhou, Liming Zhang, Xiang Zhou","doi":"10.1007/s00266-025-04837-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertrophic scars are a common fibrotic skin disorder with a high recurrence rate. While various treatment options exist, their efficacy remains uncertain. Manual fractional technology with CO<sub>2</sub> laser technology, a novel approach, has shown promise; however, its effectiveness as a standalone ablative treatment is limited. This retrospective study aims to evaluate the clinical outcomes of combining Manual fractional technology with CO<sub>2</sub> laser technology with triamcinolone acetonide and 5-fluorouracil transdermal delivery for the treatment of hypertrophic scars.</p><p><strong>Objective: </strong>This study retrospectively evaluated the clinical efficacy of MFT with CO<sub>2</sub> laser combined with transdermal triamcinolone acetonide and 5-fluorouracil in treating hypertrophic scars.</p><p><strong>Methods: </strong>A cohort of 42 patients with 48 hypertrophic scars underwent the combination therapy thrice. Scar evaluations were conducted using the patient and observer scar assessment scale (POSAS) before treatment and one month after each session. Adverse and complication reactions were monitored, and patients were followed for 6 months post-treatment. Hypertrophic scar recurrence and patient satisfaction were assessed.</p><p><strong>Results: </strong>The total POSAS score significantly decreased from pre-treatment [48.00 (43.00, 53.75) VS 21.29±7.167; p<0.001]. In the subgroup analysis, treatment outcomes varied significantly by skin type, with scar quantity and genetic factors influencing remission time. The recurrence rate during the 6-month follow-up was 6.24%, with a satisfaction rate of 83.34%. No severe adverse reactions were reported.</p><p><strong>Conclusions: </strong>The findings indicate that laser-assisted drug delivery using MFT with CO<sub>2</sub> laser demonstrates significant clinical efficacy, a low recurrence rate, and an absence of serious adverse reactions in treating hypertrophic scars. This method shows promise as a novel treatment modality for hypertrophic scars.</p><p><strong>Level of evidence iv: </strong>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .</p>","PeriodicalId":7609,"journal":{"name":"Aesthetic Plastic Surgery","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aesthetic Plastic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00266-025-04837-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Manual Fractional Technology with CO2 Laser Combined with Transdermal Drug Delivery for Hypertrophic Scar: A Retrospective Study.
Background: Hypertrophic scars are a common fibrotic skin disorder with a high recurrence rate. While various treatment options exist, their efficacy remains uncertain. Manual fractional technology with CO2 laser technology, a novel approach, has shown promise; however, its effectiveness as a standalone ablative treatment is limited. This retrospective study aims to evaluate the clinical outcomes of combining Manual fractional technology with CO2 laser technology with triamcinolone acetonide and 5-fluorouracil transdermal delivery for the treatment of hypertrophic scars.
Objective: This study retrospectively evaluated the clinical efficacy of MFT with CO2 laser combined with transdermal triamcinolone acetonide and 5-fluorouracil in treating hypertrophic scars.
Methods: A cohort of 42 patients with 48 hypertrophic scars underwent the combination therapy thrice. Scar evaluations were conducted using the patient and observer scar assessment scale (POSAS) before treatment and one month after each session. Adverse and complication reactions were monitored, and patients were followed for 6 months post-treatment. Hypertrophic scar recurrence and patient satisfaction were assessed.
Results: The total POSAS score significantly decreased from pre-treatment [48.00 (43.00, 53.75) VS 21.29±7.167; p<0.001]. In the subgroup analysis, treatment outcomes varied significantly by skin type, with scar quantity and genetic factors influencing remission time. The recurrence rate during the 6-month follow-up was 6.24%, with a satisfaction rate of 83.34%. No severe adverse reactions were reported.
Conclusions: The findings indicate that laser-assisted drug delivery using MFT with CO2 laser demonstrates significant clinical efficacy, a low recurrence rate, and an absence of serious adverse reactions in treating hypertrophic scars. This method shows promise as a novel treatment modality for hypertrophic scars.
Level of evidence iv: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
期刊介绍：
Aesthetic Plastic Surgery is a publication of the International Society of Aesthetic Plastic Surgery and the official journal of the European Association of Societies of Aesthetic Plastic Surgery (EASAPS), Società Italiana di Chirurgia Plastica Ricostruttiva ed Estetica (SICPRE), Vereinigung der Deutschen Aesthetisch Plastischen Chirurgen (VDAPC), the Romanian Aesthetic Surgery Society (RASS), Asociación Española de Cirugía Estética Plástica (AECEP), La Sociedad Argentina de Cirugía Plástica, Estética y Reparadora (SACPER), the Rhinoplasty Society of Europe (RSE), the Iranian Society of Plastic and Aesthetic Surgeons (ISPAS), the Singapore Association of Plastic Surgeons (SAPS), the Australasian Society of Aesthetic Plastic Surgeons (ASAPS), the Egyptian Society of Plastic and Reconstructive Surgeons (ESPRS), and the Sociedad Chilena de Cirugía Plástica, Reconstructiva y Estética (SCCP).
Aesthetic Plastic Surgery provides a forum for original articles advancing the art of aesthetic plastic surgery. Many describe surgical craftsmanship; others deal with complications in surgical procedures and methods by which to treat or avoid them. Coverage includes "second thoughts" on established techniques, which might be abandoned, modified, or improved. Also included are case histories; improvements in surgical instruments, pharmaceuticals, and operating room equipment; and discussions of problems such as the role of psychosocial factors in the doctor-patient and the patient-public interrelationships.
Aesthetic Plastic Surgery is covered in Current Contents/Clinical Medicine, SciSearch, Research Alert, Index Medicus-Medline, and Excerpta Medica/Embase.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
